Cargando…

Changes in Glucose Metabolism and Glycemic Status With Once-Weekly Subcutaneous Semaglutide 2.4 mg Among Participants With Prediabetes in the STEP Program

OBJECTIVE: This analysis of 3,375 adults with overweight/obesity across the Semaglutide Treatment Effect in People with obesity (STEP) 1, 3, and 4 trials evaluated whether more participants with prediabetes had normoglycemia after 68 weeks’ treatment with once-weekly semaglutide 2.4 mg plus lifestyl...

Descripción completa

Detalles Bibliográficos
Autores principales:	Perreault, Leigh, Davies, Melanie, Frias, Juan P., Laursen, Peter Nørkjaer, Lingvay, Ildiko, Machineni, Sriram, Varbo, Anette, Wilding, John P.H., Wallenstein, Signe Olrik Rytter, le Roux, Carel W.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Diabetes Association 2022
Materias:	Cardiovascular and Metabolic Risk
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9862484/ https://www.ncbi.nlm.nih.gov/pubmed/35724304 http://dx.doi.org/10.2337/dc21-1785

Ejemplares similares

Once-weekly Subcutaneous Semaglutide 2.4 mg Reduces Body Weight in Adults with Overweight or Obesity Regardless of Baseline Characteristics (STEP 1)
por: Kushner, Robert F, et al.
Publicado: (2021)

Clinically-Relevant Weight Loss is Achieved Independently of Early Weight Loss Response to Once-Weekly Subcutaneous Semaglutide 2.4 MG (STEP 4)
por: Mosenzon, Ofri, et al.
Publicado: (2021)

Effects of once-weekly semaglutide vs once-daily canagliflozin on body composition in type 2 diabetes: a substudy of the SUSTAIN 8 randomised controlled clinical trial
por: McCrimmon, Rory J., et al.
Publicado: (2020)

Abstract 9: Once-weekly subcutaneous semaglutide 2.4 mg reduces body weight in adults with overweight or obesity regardless of baseline characteristics (STEP 1)
por: Suresh, Swaroop H, et al.
Publicado: (2022)

Association between body mass index, weight loss and the chance of pregnancy in women with polycystic ovary syndrome and overweight or obesity: a retrospective cohort study in the UK
por: Haase, Christiane Lundegaard, et al.
Publicado: (2023)

Superior weight loss with once-weekly semaglutide versus other glucagon-like peptide-1 receptor agonists is independent of gastrointestinal adverse events
por: Lingvay, Ildiko, et al.
Publicado: (2020)

Efficacy and Safety of Semaglutide 2.4 MG Once-Weekly in Adults With Overweight or Obesity and Type 2 Diabetes (STEP 2)
por: Davies, Melanie, et al.
Publicado: (2021)

Efficacy and Safety of Once-Weekly Subcutaneous Semaglutide 2.4 MG in Adults With Overweight or Obesity (STEP 1)
por: Wilding, John P H, et al.
Publicado: (2021)

Efficacy of Once-Weekly Semaglutide vs Empagliflozin Added to Metformin in Type 2 Diabetes: Patient-Level Meta-analysis
por: Lingvay, Ildiko, et al.
Publicado: (2020)

Impact of patient characteristics on efficacy and safety of once-weekly semaglutide versus dulaglutide: SUSTAIN 7 post hoc analyses
por: Pratley, Richard E, et al.
Publicado: (2020)

An Indirect Comparison of Basal Insulin Plus Once-Weekly Semaglutide and Fully Optimised Basal–Bolus Insulin in Type 2 Diabetes
por: Lingvay, Ildiko, et al.
Publicado: (2022)

Abstract 10: Efficacy and safety of semaglutide 2.4 mg once- weekly in adults with overweight or obesity and type 2 diabetes (STEP 2)
por: Rahman, Syed Kasfur, et al.
Publicado: (2022)

Outcomes in GLP-1 RA-Experienced Patients Switching to Once-Weekly Semaglutide in a Real-World Setting: The Retrospective, Observational EXPERT Study
por: Lingvay, Ildiko, et al.
Publicado: (2021)

The Impact Once-Weekly Semaglutide 2.4 mg Will Have on Clinical Practice: A Focus on the STEP Trials
por: Alabduljabbar, Khaled, et al.
Publicado: (2022)

Semaglutide for the treatment of overweight and obesity: A review
por: Bergmann, Natasha Chidekel, et al.
Publicado: (2022)

Semaglutide 2.4 mg for the Treatment of Obesity: Key Elements of the STEP Trials 1 to 5
por: Kushner, Robert F., et al.
Publicado: (2020)

Gastrointestinal tolerability of once‐weekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight loss
por: Wharton, Sean, et al.
Publicado: (2021)

Weight Loss Maintenance With Once-Weekly Semaglutide 2.4 MG in Adults With Overweight or Obesity Reaching Maintenance Dose (STEP 4)
por: Rubino, Domenica M, et al.
Publicado: (2021)

Cardiovascular risk reduction with once-weekly semaglutide in subjects with type 2 diabetes: a post hoc analysis of gender, age, and baseline CV risk profile in the SUSTAIN 6 trial
por: Leiter, Lawrence A., et al.
Publicado: (2019)

Fitness, Fatness, and Survival in Adults With Prediabetes
por: McAuley, Paul A., et al.
Publicado: (2014)

Regression From Prediabetes to Normal Glucose Regulation and Prevalence of Microvascular Disease in the Diabetes Prevention Program Outcomes Study (DPPOS)
por: Perreault, Leigh, et al.
Publicado: (2019)

Insights into the early use of oral semaglutide in routine clinical practice: The IGNITE study
por: Aroda, Vanita R., et al.
Publicado: (2021)

Regression From Prediabetes to Normal Glucose Regulation Is Associated With Reduction in Cardiovascular Risk: Results From the Diabetes Prevention Program Outcomes Study
por: Perreault, Leigh, et al.
Publicado: (2014)

Semaglutide, reduction in glycated haemoglobin and the risk of diabetic retinopathy
por: Vilsbøll, Tina, et al.
Publicado: (2018)

Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension
por: Wilding, John P. H., et al.
Publicado: (2022)

Gender-related affecting factors of prediabetes on its 10-year outcome
por: Song, Xiaomin, et al.
Publicado: (2016)

Semaglutide (SUSTAIN and PIONEER) reduces cardiovascular events in type 2 diabetes across varying cardiovascular risk
por: Husain, Mansoor, et al.
Publicado: (2020)

Cost Effectiveness of Once-Weekly Semaglutide Versus Once-Weekly Dulaglutide in the Treatment of Type 2 Diabetes in Canada
por: Johansen, Pierre, et al.
Publicado: (2019)

An Indirect Treatment Comparison of Semaglutide 2.0 mg vs Dulaglutide 3.0 mg and 4.5 mg Using Multilevel Network Meta-regression
por: Lingvay, Ildiko, et al.
Publicado: (2021)

Effects of semaglutide on risk of cardiovascular events across a continuum of cardiovascular risk: combined post hoc analysis of the SUSTAIN and PIONEER trials
por: Husain, Mansoor, et al.
Publicado: (2020)

Pathobiology and Reversibility of Prediabetes in a Biracial Cohort (PROP-ABC) Study: design of lifestyle intervention
por: Dagogo-Jack, Samuel, et al.
Publicado: (2020)

Risk of hypertension in middle-aged and elderly participants with newly diagnosed type 2 diabetes and prediabetes
por: Sasaki, Nobuo, et al.
Publicado: (2020)

Different Effects of Once-weekly and Once-daily Administered GLP-1RA Semaglutide and Liraglutide on Bile Acid Diarrhea
por: Kårhus, Martin Lund, et al.
Publicado: (2022)

Real-World Use of Once-Weekly Semaglutide in Type 2 Diabetes: Results from SemaglUtide Real-world Evidence (SURE) Germany
por: Menzen, Markus, et al.
Publicado: (2023)

Safety and efficacy of semaglutide once weekly vs sitagliptin once daily, both as monotherapy in Japanese people with type 2 diabetes
por: Seino, Yutaka, et al.
Publicado: (2017)

Semaglutide Added to Basal Insulin in Type 2 Diabetes (SUSTAIN 5): A Randomized, Controlled Trial
por: Rodbard, Helena W, et al.
Publicado: (2018)

Use of a Metabolic Syndrome Severity Z Score to Track Risk During Treatment of Prediabetes: An Analysis of the Diabetes Prevention Program
por: DeBoer, Mark D., et al.
Publicado: (2018)

An indirect treatment comparison of the efficacy of semaglutide 1.0 mg versus dulaglutide 3.0 and 4.5 mg
por: Pratley, Richard E., et al.
Publicado: (2021)

Liraglutide: another reason to target prediabetes?
por: Murphy, Conor F., et al.
Publicado: (2017)

Evaluating the Long-Term Cost-Effectiveness of Once-Weekly Semaglutide Versus Once-Daily Liraglutide for the Treatment of Type 2 Diabetes in the UK
por: Johansen, Pierre, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_vmf8m13uvorinhnc45pv0eredp